Marion Odence-Ford - 08 Nov 2021 Form 4 Insider Report for OptimizeRx Corp (OPRX)

Role: General Counsel and CCO
Signature: /s/ Marion Odence-Ford
Issuer symbol: OPRX
Transactions as of: 08 Nov 2021
Net transactions value: $0
Form type: 4
Filing time: 10 Nov 2021, 15:45:32 UTC
Next filing: 15 Feb 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OPRX	Stock Option	Award	$0	-10,958	-50%	$0.000000	10,958	08 Nov 2021	Common Stock	10,958	$93.37	Direct	F1
transaction	OPRX	Restricted Stock Units	Award	$0	-5,355	-17%	$0.000000	25,335	08 Nov 2021	Common Stock	5,335		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Stock Option will vest 1/3 at the end of each anniversary from issuance.
F2	Each restricted stock unit represents a contingent right to receive one share of the OptimizeRx's common stock. The restricted stock units will vest 1/3 at the end of each anniversary from issuance. Any restricted stock unit that has not been earned and vested as of the third anniversary of the grant date will be forfeited. Vesting of the restricted stock units shall accelerate upon a qualifying termination.

Content

The Stock Option will vest 1/3 at the end of each anniversary from issuance.

Each restricted stock unit represents a contingent right to receive one share of the OptimizeRx's common stock. The restricted stock units will vest 1/3 at the end of each anniversary from issuance. Any restricted stock unit that has not been earned and vested as of the third anniversary of the grant date will be forfeited. Vesting of the restricted stock units shall accelerate upon a qualifying termination.